title: Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor.
authors: Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.
authors: A
authors: A
authors: Enshaei
authors: C J
authors: CJ
authors: Schwab
authors: Z J
authors: ZJ
authors: Konn
authors: C D
authors: CD
authors: Mitchell
authors: S E
authors: SE
authors: Kinsey
authors: R
authors: R
authors: Wade
authors: A
authors: A
authors: Vora
authors: C J
authors: CJ
authors: Harrison
authors: A V
authors: AV
authors: Moorman
mesh_terms: D000293:Adolescent; D014408:Biomarkers, Tumor / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D015331:Cohort Studies; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D008297:Male; D054547:National Cancer Institute (U.S.); D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D014481:United States; D000097764:ETS Translocation Variant 6 Protein
chemical_list: D014408:Biomarkers, Tumor; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein